Trial Profile

A phase 2 study of BOsutinib Gradual Increase as a second or third line treatment for chronic myeloid leukemia in chronic phase

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bosutinib (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions
Acronyms BOGI Trial

Most Recent Events

01 Oct 2024 Results published in the International Journal of Hematology
12 Dec 2023 Results(Between Feb 4, 2019, and May 24, 2022, n=35 patients), presented at the 65th American Society of Hematology Annual Meeting and Exposition
19 Apr 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com